Health & Medicine

STAT+: Eli Lilly's 'triple-G' drug leads to significant blood sugar, weight reductions in diabetes trial

Ali NematiAli Nemati4 days ago24 sec read2 views

Eli Lilly's investigational drug retatrutide showed significant reductions in blood sugar and weight loss in diabetes patients, outperforming placebo and rivaling Lilly’s Mounjaro. The notable weight loss of 15.3% at the highest dose could mark a substantial advancement for diabetes treatment, offering hope for more effective management of both blood sugar and obesity.

Read the full article at STAT News


Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

2
Comments
Ali Nemati
Ali NematiWritten by Ali
View all posts

Related Articles